| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.069 | 0.04 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.079 | 0.04 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.066 | 0.04 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.071 | 0.04 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.13 | 0.04 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | 0.55 | 0.04 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.064 | 0.04 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | -0.06 | 0.05 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | -0.069 | 0.05 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.095 | 0.05 |